Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: Ten-year follow-up data analyzed with marginal structural models and propensity score methods

Integrative Cancer Therapies

Volumn 10, Issue 3, 2011, Pages 260-279

  McCulloch, Michael ^a,b   Broffman, Michael ^a   Van Der Laan, Mark ^b   Hubbard, Alan ^b   Kushi, Lawrence ^c   Kramer, Alan ^d   Gao, Jin ^e   Colford Jr , John M ^b  

^a Pine Street Foundation ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE   (United States)

^d San Francisco Oncology Associates   (United States)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

chemotherapy; Chinese herbal medicine; lung cancer; marginal structural models; propensity score; radiotherapy; survival; vitamins

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CURCUMIN; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; FISH OIL; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GRAPE SEED EXTRACT; HERBACEOUS AGENT; MELATONIN; SPIRULINA EXTRACT; THYMUS EXTRACT; UBIDECARENONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARTILAGE; CHINESE MEDICINE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HERBAL MEDICINE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TEA; VITAMIN SUPPLEMENTATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HERBAL MEDICINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; NEOPLASM STAGING; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VITAMINS;

EID: 84855363742     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411406439     Document Type: Article

References (101)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 ; 56: 106-130
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008 ; 359: 1367-1380
3. Schiller JH, Storer B, Dreicer R, et al. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst. 1989 ; 81: 1739-1743 (Pubitemid 19275914)
4. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2004 ; ( 4 ):
5. Rowell N, O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004 ; (4). CD002140
6. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2004 ; (4). CD002142
7. Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer. 2005 ; 47: 81-3 (Pubitemid 39643244)
8. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005 ; 23: 2926-2936 (Pubitemid 46224111)
9. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008 ; 26: 4617-4625
10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 2. J Clin Oncol. 2004 ; 22: 785-794 (Pubitemid 41103589)
11. Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008 ; 20: 104-111 (Pubitemid 350190989)
12. Molassiotis A, Panteli V, Patiraki E, et al. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract. 2006 ; 12: 34-39 (Pubitemid 43056766)
13. McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006 ; 24: 419-430 (Pubitemid 46655594)
14. Jatoi A, Williams B, Nichols F, et al. Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005 ; 49: 77-84 (Pubitemid 40798096)
15. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 ; 291: 2720-2726 (Pubitemid 38725421)
16. Smith CA, Coyle ME. Recruitment and implementation strategies in randomised controlled trials of acupuncture and herbal medicine in women's health. Complement Ther Med. 2006 ; 14: 81-86 (Pubitemid 43210580)
17. West SG, Duan N, Pequegnat W, et al. Alternatives to the randomized controlled trial. Am J Public Health. 2008 ; 98: 1359-1366
18. Cole SR, Hernan MA, Margolick JB, et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol. 2005 ; 162: 471-478 (Pubitemid 41191433)
19. Petersen ML, Wang Y, van der Laan MJ, et al. Assessing the effectiveness of antiretroviral adherence interventions: using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr. 2006 ; 43: S96 - S103 (Pubitemid 44885647)
20. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001 ; 96: 440-448
21. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000 ; 56: 779-788
22. Mortimer KM, Neugebauer R, van der Laan M, et al. An application of model-fitting procedures for marginal structural models. Am J Epidemiol. 2005 ; 162: 382-388 (Pubitemid 41389720)
23. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 ; 11: 550-560 (Pubitemid 30660034)
24. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003 ; 14: 680-686 (Pubitemid 40417015)
25. Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects. Stat Med. 2004 ; 23: 1991-2003 (Pubitemid 38968024)
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 ; 70: 41-55
27. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984 ; 79: 516-524
28. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992 ; 21: 837-841
29. Broffman M, McCulloch M, See C, et al Botanical Medicine in Clinical Practice. Preedy RRWVR, ed. Wallingford, UK: CABI ; 366-76.
30. Grondin SC, Liptay MJ. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002 ; 11: 181-190 (Pubitemid 35356567)
31. SEER Program: Comparative Staging Guide for Cancer. Bethesda, MD: National Cancer Institute ; 1993:
32. SEER Program Coding and Staging Manual 2007. Johnson CH Adamo M, ed. Bethesda, MD: National Cancer Institute ; 2007:
33. Kaplan ER, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc. 1958 ; 53: 457-481
34. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol. 1972 ; 34: 187-220
35. Robins JM Proceedings of the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association ; 1997: 1-10.
36. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979 ; 7: 1-26
37. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002 ; 2: 358-377
38. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 ; 127 (8, pt 2). 757-763 (Pubitemid 27446562)
39. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007 ; 4: e297
40. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001 ; 19: 1734-1742 (Pubitemid 32230875)
41. Wisnivesky JP, Bonomi M, Henschke C, et al. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest. 2005 ; 128: 1461-1467 (Pubitemid 41324433)
42. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006 ; 52: 207-212
43. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 ; 16: 2459-2465 (Pubitemid 28309041)
44. Valdes S, Garcia E, Perez H, et al. Length of diagnostic delay in patients with non-small-cell lung cancer. MEDICC Rev. 2010 ; 12: 29-32
45. Macpherson H. Pragmatic clinical trials. Complement Ther Med. 2004 ; 12: 136-140 (Pubitemid 39618841)
46. Helyer LK, Chin S, Chui BK, et al. The use of complementary and alternative medicines among patients with locally advanced breast cancer: a descriptive study. BMC Cancer. 2006 ; 6: 39
47. Dejardin O, Bouvier AM, Faivre J, et al. Access to care, socioeconomic deprivation and colon cancer survival. Aliment Pharmacol Ther. 2008 ; 27: 940-949 (Pubitemid 351537655)
48. Ou SH, Zell JA, Ziogas A, et al. Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer. 2008 ; 112: 2011-2020 (Pubitemid 351574077)
49. Goodman MT, Kolonel LN, Wilkens LR, et al. Smoking history and survival among lung cancer patients. Cancer Causes Control. 1990 ; 1: 155-163
50. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004 ; 57: 597-609 (Pubitemid 38891497)
51. Toh CK, Wong EH, Lim WT, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004 ; 126: 1750-1756
52. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer. 2004 ; 44: 287-293 (Pubitemid 38609436)
53. Lefebvre G, Delaney JA, Platt RW. Impact of mis-specification of the treatment model on estimates from a marginal structural model. Stat Med. 2008 ; 27: 3629-3642
54. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008 ; 168: 656-664
55. Gordon NP, Lin TY. Use of complementary and alternative medicine by the adult membership of a large northern California health maintenance organization, 1999. J Ambul Care Manage. 2004 ; 27: 12-24 (Pubitemid 38031965)
56. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on pulmonary function in lung cancer. Lung Cancer. 1994 ; 10: S219-230
57. Van Houtte P, Danhier S, et al. Toxicity of combined radiation and chemotherapy in non-small cell lung cancer. Lung Cancer. 1994 ; 10: S271-280
58. Brundage MD, Davidson JR, et al. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology. 1997 ; 15 (1). 330-340 (Pubitemid 27020591)
59. Zhong L, Goldberg MS, Gao YT, et al. A population-based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology. 2001 ; 12: 695-700 (Pubitemid 33138163)
60. Liang W, Binns CW, Jian L, et al. Does the consumption of green tea reduce the risk of lung cancer among smokers?. Evid Based Complement Alternat Med. 2007 ; 4: 17-22 (Pubitemid 46410888)
61. Hecht SS, Upadhyaya P, Wang M, et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002 ; 23: 1455-1461 (Pubitemid 35021225)
62. Qanungo S, Wang M, Nieminen AL. N-Acetyl-l-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts. J Biol Chem. 2004 ; 279: 50455-50464 (Pubitemid 39577864)
63. Simkeviciene V, Straukas J, Uleckiene S. N-acetyl-l-cysteine and 2-amino-2-thiiazoline N-acetyl-l-cysteinate as a possible cancer chemopreventive agents in murine models. Acta Biol Hung. 2002 ; 53: 293-298 (Pubitemid 34961452)
64. Goldman Y, Peled A, Shinitzky M Cancer Res. 2000: 350-358.
65. Chen HW, Lee JY, Huang JY, et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 2008 ; 68: 7428-7438
66. Lee J, Im YH, Jung HH, et al. Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. Biochem Biophys Res Commun. 2005 ; 334: 313-318 (Pubitemid 40982371)
67. Zhang J, Qi H, Wu C. Research of anti-proliferation of curcumin on A549 human lung cancer cells and its mechanism [in Chinese]. Zhong Yao Cai. 2004 ; 27: 923-927
68. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, et al. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 2004 ; 208: 163-170 (Pubitemid 38624157)
69. Hong YS, Ham YA, Choi JH, et al. Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non small cell lung cancer cell lines. Exp Mol Med. 2000 ; 32: 127-134
70. Sugiyama T, Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim Biophys Acta. 2003 ; 1653: 47-59 (Pubitemid 37487647)
71. Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun. 2007 ; 360: 233-237 (Pubitemid 46994711)
72. Kakuda T. Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull. 2002 ; 25: 1513-1518 (Pubitemid 39663661)
73. Nathan PJ, Lu K, Gray M, et al. The neuropharmacology of l-theanine(N-ethyl-l-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006 ; 6: 21-30 (Pubitemid 44964090)
74. Ioannides C, Hall DE, Mulder DE, et al. A comparison of the protective effects of N-acetyl-cysteine and S-carboxymethylcysteine against paracetamol-induced hepatotoxicity. Toxicology. 1983 ; 28: 313-321 (Pubitemid 14237212)
75. Sprague CL, Elfarra AA. Protection of rats against 3-butene-1,2-diol- induced hepatotoxicity and hypoglycemia by N-acetyl-l-cysteine. Toxicol Appl Pharmacol. 2005 ; 207: 266-274 (Pubitemid 41207919)
76. Varma PS, Aruna K, Rukkumani R, et al. Alcohol and thermally oxidized PUFA induced oxidative stress: role of N-acetyl cysteine. Ital J Biochem. 2004 ; 53: 10-15
77. Berend N. Inhibition of bleomycin lung toxicity by N-acetyl cysteine in the rat. Pathology. 1985 ; 17: 108-110 (Pubitemid 15105043)
78. Gon Y, Hashimoto S, Nakayama T, et al. N-acetyl-l-cysteine inhibits bleomycin-induced interleukin-8 secretion by bronchial epithelial cells. Respirology. 2000 ; 5: 309-313 (Pubitemid 32049491)
79. Trizna Z, Schantz SP, Hsu TC. Effects of N-acetyl-l-cysteine and ascorbic acid on mutagen-induced chromosomal sensitivity in patients with head and neck cancers. Am J Surg. 1991 ; 162: 294-298
80. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy [in Japanese]. Gan To Kagaku Ryoho. 1982 ; 9: 116-121 (Pubitemid 12158009)
81. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007 ; 97: 1028-1034 (Pubitemid 47587008)
82. Jagetia GC. Radioprotective potential of plants and herbs against the effects of ionizing radiation. J Clin Biochem Nutr. 2007 ; 40: 74-81 (Pubitemid 46623808)
83. Chae S, Kang KA, Chang WY, et al. Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem. 2009 ; 57: 5777-5782
84. Takeda T, Kamiura S, Kimura T. Effectiveness of the herbal medicine daikenchuto for radiation-induced enteritis. J Altern Complement Med. 2008 ; 14: 753-755
85. Liu WC, Wang SC, Tsai ML, et al. Protection against radiation-induced bone marrow and intestinal injuries by Cordyceps sinensis, a Chinese herbal medicine. Radiat Res. 2006 ; 166: 900-907
86. Xun C, Shen N, Li B, et al. Radiation mitigation effect of cultured mushroom fungus Hirsutella sinensis (CorImmune) isolated from a Chinese/Tibetan herbal preparation: Cordyceps sinensis. Int J Radiat Biol. 2008 ; 84: 139-149 (Pubitemid 351197938)
87. Kim SH, Lee HJ, Kim JS, et al. Protective effect of an herbal preparation (HemoHIM) on radiation-induced intestinal injury in mice. J Med Food. 2009 ; 12: 1353-1358
88. Han G, Zhou YF, Zhang MS, et al. Angelica sinensis down-regulates hydroxyproline and Tgfb1 and provides protection in mice with radiation-induced pulmonary fibrosis. Radiat Res. 2006 ; 165: 546-552
89. Tian YP, Wang QC. Rectal radiation injuries treated by Shen Ling Bai Zhu powders combined with rectal administration of western drugs [in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 ; 28: 159-160
90. Dou YQ, Yang MH, Wei ZM, et al. The study of early application with Dixiong Decoction for non-small cell lung cancer to decrease the incidence and severity of radiation pneumonitis: a prospective, randomized clinical trial. Chin J Integr Med. 2010 ; 16: 411-416
91. Kikawa KD, Herrick JS, Tateo RE, et al. Induced oxidative stress and cell death in the A549 lung adenocarcinoma cell line by ionizing radiation is enhanced by supplementation with docosahexaenoic acid. Nutr Cancer. 2010 ; 62: 1017-1024
92. Lee JC, Kinniry PA, Arguiri E, et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat Res. 2010 ; 173: 590-601
93. Yildiz OG, Soyuer S, Saraymen R, et al. Protective effects of caffeic acid phenethyl ester on radiation induced lung injury in rats. Clin Invest Med. 2008 ; 31: E242 - E247
94. Bese NS, Munzuroglu F, Uslu B, et al. Vitamin E protects against the development of radiation-induced pulmonary fibrosis in rats. Clin Oncol (R Coll Radiol). 2007 ; 19: 260-264 (Pubitemid 46547273)
95. Sener G, Jahovic N, Tosun O, et al. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci. 2003 ; 74: 563-572 (Pubitemid 37410348)
96. Mantovani G, Maccio A, Melis G, et al. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer. 2000 ; 86: 842-847 (Pubitemid 30350200)
97. Beardsley TR, Pierschbacher M, Wetzel GD, et al. Induction of T-cell maturation by a cloned line of thymic epithelium (TEPI). Proc Natl Acad Sci U S A. 1983 ; 80: 6005-6009 (Pubitemid 14228232)
98. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007 ; 59: 14-20 (Pubitemid 47549776)
99. Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003 ; 35: 12-15 (Pubitemid 36819165)
100. Norsa A, Martino V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status. Cancer Biother Radiopharm. 2006 ; 21: 68-73
101. Lissoni P, Tisi E, Barni S, et al. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer. 1992 ; 66: 155-158